ICD-O-3
Carcinoma, Squamous cell, NOS 8070/3
Site Code: Cervix NOS C53.9

12/29/10
lw

Patient Name: [redacted]
DOB: [redacted] MRN: [redacted]
Accession: [redacted] PAN: [redacted]

# Surgical Pathology Report

[redacted] Final

SURGICAL PATHOLOGY REPORT
FINAL

Patient Name: [redacted]
Address: [redacted]
Gender: F
DOB: [redacted]

Service: Gynecology
Location:
MRN: [redacted]
Hospital #: [redacted]
Patient Type:

Accession #: [redacted]
Taken: [redacted]
Received: [redacted]
Accessioned: [redacted]
Reported: [redacted]

Physician(s):
[redacted]

Other Related Clinical Data:

**DIAGNOSIS:**
ECTOCERVIX, BIOPSY
- INVASIVE MODERATELY TO POORLY DIFFERENTIATED SQUAMOUS CELL CARCINOMA
- LYMPHVASCULAR INVASION PRESENT

[redacted] By this signature, I attest that the above diagnosis is based upon my personal examination of the slides(and/or other material indicated in the diagnosis).

[redacted] D.
***Report Electronically Reviewed and Signed Out By [redacted] ***

Microscopic Description and Comment:
Microscopic examination substantiates the above cited diagnosis. ([redacted])

[redacted]

History:
The patient is a [redacted] year old woman with a 6 cm cervical mass with no endometrial involvement. Clinical stage 1B2. Operative procedure: Cervical biopsy.
Specimen(s) Received:
A: CERVIX

Gross Description
The specimen is received in a formalin-filled container labeled [redacted] and "cervical biopsies." It consists of two irregular, gray-white mucosal tissue fragments measuring 0.7 x 0.4 x 0.3 cm and 0.6 x 0.5 x 0.4 cm. The excision margin cannot be assessed. Serially sectioned. Labeled A1. Jar 0.

[redacted] 16:53 [redacted]
The performance characteristics of some immunohistochemical stains, fluorescence in-situ hybridization tests and immunophenotyping by flow cytometry cited in this report (if any) were determined by the [redacted] at [redacted] as part of an ongoing quality assurance program and in compliance with [redacted] ally mandated regulations drawn from the Clinical Laboratory Improvement Act of 1988 (CLIA '88). Some of these tests rely on the use of "analyte specific reagents" and are subject to specific labeling

[redacted] Printed from [redacted]

UUID:541610BD-6ACC-4EE7-8942-8524C8BE0515
TCGA-C5-A1BN-01B-PR

Redacted

| Criteria | Yes | No |
|---|---|---|
| Diagnosis Discrepancy | | X |
| Primary Tumor Site Discrepancy | | X |
| HIPAA Discrepancy | | X |
| Prior Malignancy History | | X |
| Dual/Synchronous Primary Noted | | X |

Case is (circle): QUALIFIED / DISQUALIFIED
Reviewer Initials: MB lw Date Reviewed: 12-29-10